Occoris inhaler technology to make debut at RDD
Team Consulting will unveil prototype designs using the multi-platform inhaler ‘engine’
Designed primarily for delivering systemic treatments beyond the typically inhaled topical asthma and COPD, such as vaccines, pain relief and insulin, the Occoris ‘engine’ is ultra-small, active and achieves accurate and repeatable delivery of API-only formulations, the firm says.
The Ickleton, Cambridgeshire company will showcase prototypes for a single-use disposable inhaler, a multi-unit dose inhaler and a multi-dose inhaler – demonstrating the technology’s multi-platform credentials, and to illustrate the numerous design possibilities afforded by Occoris.
Team Consulting says it developed the technology after identifying a number of factors that are likely to shape the respiratory drug delivery market of the future.
First, asthma and COPD inhalers typically use an inert carrier fraction to dilute the small quantities of API. Inhalers that treat conditions beyond asthma and COPD will need to deliver a wide range of dosages that do not require a carrier fraction.
Second, inhalers for treating conditions such as diabetes, pain relief or delivering vaccines will require very different designs. Team Consulting says the simplicity and small size (around the same size as a garden pea) of the Occoris engine gives designers flexibility in form factor and materials. For example, one of the concepts on show at RDD will be for mass vaccination and can be produced largely out of recyclable cardboard.
Third, regulators will demand much tighter dose content uniformity, higher delivery efficiencies and better independency of flow rate from inhalers.
Team Consulting says early indications are that inhalers that use the active Occoris engine will deliver highly accurate dosage and repeatable performance.
‘Delivering drug via the pulmonary route offers so many advantages over needles and tablets. The drug is quickly absorbed by the body, in powder form it doesn’t require cold storage and there is no user anxiety or danger of needle-stick injuries,’ says David Harris, head of respiratory drug delivery at Team Consulting.
‘With our Occoris technology we are opening up a wide range of new opportunities beyond the traditional and highly competitive asthma and COPD market, which will help our pharmaceutical clients to establish new revenue streams.’
You may also like
Packaging
To connect or not to connect, that is the question: the need and usability of data should be the deciding factor
Read moreAhead of his session exploring the connectivity of medical devices at Pharmapack Europe 2022 (18-19 May, Paris Expo, Porte de Versailles), the largest hub for the pharma packaging and drug delivery industry, Dr Kevin Robinson speaks to Thomas Watts (TW), Engineering Consultant, Team Consulting
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
Packaging
To connect or not to connect, that is the question: the need and usability of data should be the deciding factor
Ahead of his session exploring the connectivity of medical devices at Pharmapack Europe 2022 (18-19 May, Paris Expo, Porte de Versailles), the largest hub for the pharma packaging and drug delivery industry, Dr Kevin Robinson speaks to Thomas Watts (TW), Engineering Consultant, Team Consulting
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists